Name (Synonyms) | Correlation | |
---|---|---|
drug1166 | To assess for development of IgG antibodies against SARS-CoV2 Wiki | 0.71 |
drug239 | Camostat Mesilate Wiki | 0.71 |
drug532 | Hydroxychloroquine Sulfate Loading Dose Wiki | 0.50 |
drug533 | Hydroxychloroquine Sulfate Regular dose Wiki | 0.50 |
drug262 | Chloroquine Wiki | 0.27 |
drug850 | Placebo Wiki | 0.12 |
drug505 | Hydroxychloroquine Wiki | 0.08 |
Name (Synonyms) | Correlation | |
---|---|---|
D003333 | Coronaviridae Infections NIH | 0.41 |
D012327 | RNA Virus Infections NIH | 0.35 |
D014777 | Virus Diseases NIH | 0.10 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.08 |
D003141 | Communicable Diseases NIH | 0.07 |
D018352 | Coronavirus Infections NIH | 0.07 |
D007239 | Infection NIH | 0.05 |
Name (Synonyms) | Correlation |
---|
There are 2 clinical trials
To create a protocol for treatment of Pakistani patients with SARS-CoV-2 infection with an intent to reduce burden on institutional healthcare services by determining efficacy of different quinone drug dosing regimens in controlling SARS-CoV-2 infection for asymptomatic patients.
Description: Percentage of patients who become RT-PCR negative with two RT-PCR tests performed at day 6 and day 7
Measure: RT-PCR negative status Time: 6-7 daysDescription: Time to progression to next stage of SARS-CoV-2 disease severity index
Measure: Progression of symptoms Time: 7 daysDescription: Time to onset of fever (temperature greater than 100 degree F), cough, or shortness of breath (respiratory rate >22 per minute).
Measure: Development of Symptoms Time: 7 daysDescription: Drug related adverse events as determined by data safety and monitoring board (DSMB)
Measure: Adverse events Time: 7 daysPurpose: To determine the number of asymptomatic individuals who have antibodies to SARS-CoV-2, the virus which causes COVID-19
Description: Presence or absence of IgG antibodies to SARS-CoV2
Measure: Percentage of Asymptomatic patients with an IgG response from SARS-CoV-2 infection. Time: at enrollmentDescription: swab for presence of SARS-CoV-2 virus
Measure: Percentage of Asymptomatic patients with viral presence of SARS-CoV-2 infection. Time: at enrollment